Rheumatoid Arthritis News

The effects of climate change break down epithelial barriers, enabling pollutants and other materials to penetrate the body and trigger or exacerbate autoimmune diseases, according to a review published in Frontiers in Science.

A biosimilar for golimumab has demonstrated therapeutic equivalence in rheumatoid arthritis, with no clinically meaningful safety differences, according to a press release from the manufacturer.

Patients in rheumatoid arthritis remission who tapered off conventional synthetic disease-modifying antirheumatic drugs had higher risks for flares, with two methods failing to reach non-inferiority vs. stable dosage, according to data.

Patients with rheumatoid arthritis may be able to tame their disease progression and inflammation by adopting elements of the Mediterranean diet such as lowering sugar intake and incorporating protein in the form of fish or plant-based sources.

Patients receiving daily tofacitinib doses of 10 mg for rheumatoid arthritis demonstrate an increased risk for venous thromboembolism and pulmonary embolism, compared with those taking TNF inhibitors, according to data.

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

Patients with immune-mediated diseases have higher rates of adverse pregnancy outcomes such as preeclampsia and pre-term delivery, with lupus and systemic sclerosis conferring the largest risks, according to data published in Rheumatology.

Hydroxychloroquine use for systemic lupus erythematosus or rheumatoid arthritis in the first trimester of pregnancy does not significantly increase the risk for major congenital malformations, according to data published in Rheumatology.

Archaeologists in Egypt recently discovered evidence of an ancient case of rheumatoid arthritis, potentially filling in the timeline of humanity’s relationship with autoimmune disease.

Since the beginning of the COVID-19 pandemic, there has been a “significant decrease” in the risk for post-acute sequelae of COVID-19 among patients with rheumatic diseases, according to data published in The Journal of Rheumatology.